Examining the Impact of Cardiovascular Safety in the Management of Type 2 Diabetes: Managed Care Considerations in an Evolving Treatment Paradigm

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by an educational grant from
AstraZeneca LP

The American Diabetes Association (ADA) estimates that 9.4% of the U.S. population has diabetes. About 90-95% of adults who have diabetes have type 2 Diabetes Mellitus (DM). According to the Centers for Disease Control (CDC), uncontrolled type 2 DM (T2DM) doubles a person’s risk for death, and on average individuals with T2DM lose 10-15 years of life. While the prevalence of diabetes continues to rise, a new generation of treatments has become available that allow the individualization of T2DM in the past few years. There have been many questions in member surveys and past program evaluations about the best practices in regards to the role of combination therapies comprised of SGLT-2 inhibitors in the management of type 2 diabetes. Additionally, new clinical trial data has become available for antidiabetic therapies that have shown improved outcomes for reducing macrovascular risk factors associated with T2DM, including hypertension and heart failure.

Upon completion of this activity, participants will be able to:

  • Explore the relationship between cardiovascular disease (CVD) and diabetes, including risk factors and patient outcomes

  • Evaluate the role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk based intervention strategy that targets glucose control and cardiovascular risk factors

  • Compare and contrast the mechanisms of action, safety and efficacy of current and emerging therapies for achieving individualized target goals in types 2 diabetes (T2DM)

  • Analyze recent guideline recommendations and available data to support appropriate individualized type 2 diabetes management based on patient clinical characteristics and preferences

  • Incorporate evidence from recent CVOTs to develop T2DM treatment plans that improve glycemic control and reduce CV risk when appropriate based on guidelines, benefits and risks of second-line antihyperglycemic treatments, and patient profiles and preferences

  • Assess methods to enable optimal cost management of SGLT2 inhibitors to be realized by multiple type 2 diabetes and CVD stakeholders including managed care organizations

Faculty: Gary Owens, MD
Gary Owens Associates


Dr. Owens serves on an advisory board for Eli Lilly. He serves as a consultant for Johnson & Johnson. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by an educational grant from
AstraZeneca LP

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue